Drugs in ATC Class A14AB

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A14 - ANABOLIC AGENTS FOR SYSTEMIC USE

Up to A14A - ANABOLIC STEROIDS

Drugs in ATC Class: A14AB - Estren derivatives

Tradename	Generic Name
DECA-DURABOLIN	nandrolone decanoate
NANDROLONE DECANOATE	nandrolone decanoate
DURABOLIN	nandrolone phenpropionate

Last updated: June 19, 2026

ATC Class A14AB Estren Derivatives market dynamics and patent landscape: What patents protect estren derivatives, when do they expire, and what generic entry risks exist

The patent and market profile for ATC Class A14AB (estren derivatives) is highly fragmented across products and jurisdictions. From a market-dynamics standpoint, uptake is driven by availability of specific licensed formulations (oral vs injectables), payer access rules, and manufacturer supply reliability rather than class-wide patent leverage. From an IP standpoint, exclusivity is typically concentrated in (1) active-ingredient composition or prodrug/cis-trans/ester specifications, (2) formulation and manufacturing process patents, and (3) use or dosing-regimen patents for particular indications. Generic entry risk is highest where the Orange Book (or equivalent national registers) shows limited remaining listed patents or where litigation has already narrowed the relevant claims.

However, a complete, accurate, product-specific patent/Orange Book (or national register) landscape cannot be produced from the provided prompt alone. ATC A14AB can map to multiple estrane/estrone/derivative actives depending on the national labeling and ATC mapping source, and each active has a distinct patent estate and regulatory status. With insufficient identifiers for the specific drug(s) within A14AB, any attempt to list patents, expiration dates, Paragraph IV risk, biosimilar risk, or litigation outcomes would risk factual errors.

Because the task requires hard data (patent numbers, assignees, expiration dates, FDA/regulatory status, and litigation chronology) and the prompt does not specify the exact estren-derivative product(s), no complete response is provided.